GSK and Novartis Agree Multi-Billion Asset Swap

Gerald Clarke

Pharma restructuring continues unabated and the latest deals to be announced are some of the biggest yet. Most of the major players in the market have undergone dramatic shifts in how they do business and have been refocusing on key areas (read: firing people in droves.) This ideal of focusing on key areas has been put to mutual benefit of GSK and Novartis who will be swapping business in therapeutic areas like children swapping Pokémon cards that they desire from each others’ c...
To continue reading this story get free access